Cellmid Limited (ASX:CDY) has been granted key US and European patents for its midkine antibodies securing comprehensive protection over these antibodies to treat cancer, inflammatory diseases and auto-immune disorders.
Simultaneous granting of the two patents in the US and key European territories represents a major milestone in the company’s midkine therapeutic program.
The humanised therapeutic antibody covered by these patents is one of the lead drugs in the midkine program and adds commercial value to the comprehensive intellectual property portfolio around midkine.
Shares have been up almost 12% to an intra-day high of 23.5 cents.
Cellmid has received notice of allowance for the Improved midkine antibody patent from the USPTO (Application No 15/518,849).
In addition, and following a ‘Notification of Intention to Grant’ from the European Patent Office in August 2019 for the Improved midkine antibody patent (Application No 15849875.8), the EPO has issued a ‘Decision to Grant’.
Patent family protection
This patent family protects the composition of humanised antibodies that recognise regions within the C-domain of the midkine protein.
It also protects the use of these humanised midkine antibodies in several disease settings including the diagnosis and treatment of cancer, inflammatory diseases and autoimmune conditions such as multiple sclerosis.
Midkine is a growth factor that is highly expressed during embryonic development and modulates many important biological interactions such as cell growth, cell migration and cellular adherence.
These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing.
Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders.
Expression is often evident very early in disease onset, even before any apparent physical symptoms and, accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases.
Midkine is only evident in a disease context and targeting midkine is not expected to harm normal healthy tissues.
IP position underpinned
Cellmid’s newly granted midkine antibody patents and allied patent families underpin the company’s IP position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer, chronic inflammation, as well as functional disorders in T-regulatory cells and activated neutrophils associated with autoimmune diseases.
The company’s total midkine patent portfolio comprises 67 patents and applications in 12 patent families, including patents covering the use of midkine and anti-MK agents for therapeutic purposes in a number of diseases such as cancer, inflammatory conditions and autoimmune diseases.